^
Association details:
| Biomarker: | TP53 mutation + PIK3CA mutation + CD74 mutation |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | carboplatin (Tubulin polymerization promoter) + paclitaxel (Bcl2 inhibitor, Tubulin polymerization promoter) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Case Report: Long-Term Survival With Anlotinib in a Patient With Advanced Undifferentiated Large-Cell Lung Cancer and Rare Tonsillar Metastasis
Published date:
06/24/2021
Excerpt:
A 70-year-old man with a 20-year history of smoking...diagnosed with undifferentiated large-cell lung cancer of the left lung...Next generation sequencing (NGS, Geneseeq Technology Inc) found mutations in TP53, PIK3CA, and CD74...the patient received albumin-bound paclitaxel (200 mg on d 1 and 8) + carboplatin (450 mg on d 1) chemotherapy for four cycles. Chest CT (May 15, 2019) showed a 93 * 62 mm mass near the left upper mediastinum, and the efficacy was evaluated as progressive disease (PD).
DOI:
10.3389/fonc.2021.680818
